LifeStance Health Group, Inc. (NASDAQ:LFST) Receives $8.70 Average Price Target from Brokerages

Shares of LifeStance Health Group, Inc. (NASDAQ:LFST - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the six ratings firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among brokers that have covered the stock in the last year is $8.70.

A number of equities research analysts have recently commented on LFST shares. William Blair reaffirmed an "outperform" rating on shares of LifeStance Health Group in a research note on Friday. The Goldman Sachs Group upgraded LifeStance Health Group from a "neutral" rating to a "buy" rating and set a $10.00 price objective for the company in a report on Monday, December 16th. Finally, Barclays boosted their target price on shares of LifeStance Health Group from $6.00 to $7.00 and gave the stock an "underweight" rating in a research report on Monday, November 11th.

LifeStance Health Group Trading Up 1.4 %

LFST traded up $0.11 during trading on Friday, reaching $8.02. 2,832,852 shares of the company's stock were exchanged, compared to its average volume of 1,298,169. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 0.19. LifeStance Health Group has a one year low of $4.64 and a one year high of $8.61. The stock has a market capitalization of $3.07 billion, a PE ratio of -30.85 and a beta of 1.28. The firm has a fifty day moving average price of $7.81 and a two-hundred day moving average price of $7.26.

Remove Ads

Hedge Funds Weigh In On LifeStance Health Group

Several hedge funds have recently bought and sold shares of the company. Forum Financial Management LP purchased a new position in shares of LifeStance Health Group during the 4th quarter valued at $110,000. Neo Ivy Capital Management grew its position in LifeStance Health Group by 26,132.3% during the fourth quarter. Neo Ivy Capital Management now owns 182,052 shares of the company's stock worth $1,341,000 after buying an additional 181,358 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of LifeStance Health Group by 16.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 604,321 shares of the company's stock valued at $4,454,000 after acquiring an additional 87,502 shares in the last quarter. Vident Advisory LLC purchased a new stake in shares of LifeStance Health Group in the 4th quarter valued at about $156,000. Finally, Two Sigma Advisers LP purchased a new position in shares of LifeStance Health Group during the fourth quarter worth about $183,000. Hedge funds and other institutional investors own 85.50% of the company's stock.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.